Xuefeng Kan

10PUBLICATIONS
23CO-AUTHORS
Predictive and prognostic markersMedical biotechnology diagnostics (incl. biosensors)Cancer therapy (excl. chemotherapy and radiation therapy)Organic chemistry not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 19, 2026
Hepatic immune prognostic index as a prognostic biomarker in hepatocellular carcinoma patients treated with transarterial chemoembolization.

|Mar 19, 2026
Hypoxia-related and immune phenotype-related fusion model for non-invasive prognostication of hepatocellular carcinoma treated by TACE: a multicentre study.

Yusheng Guo, Guilin Zhang, Xiaona Fu

|Jan 02, 2026
Generative AI-based low-dose digital subtraction angiography for intra-operative radiation dose reduction: a randomized controlled trial.

Huangxuan Zhao, Yaowei Bai, Lei Chen

|Sep 24, 2025
Anti-CD24 Antibody Plus Liposomal Doxorubicin for the Management of Residual Cancers After Incomplete Radiofrequency Ablation.

Jiayun Liu, Bo Sun, Jing Li

|May 21, 2025
Atezolizumab Plus Bevacizumab Combined with or without Transarterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Study.

Jing Li, Yaowei Bai, Fu Xiong

|Apr 13, 2025
Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma.

Bo Sun, Jiayun Liu, Xiaocui Liu

Pageof 2

Frequent Collaborators

4 joint publications

Chuansheng Zheng

2 joint publications

Yanyan Cao

2 joint publications

Fu Xiong

2 joint publications

Lian Yang